Abstract
LKB1/STK11 is a tumor suppressor and a negative regulator of mammalian target of rapamycin signaling. It is inactivated in 30% of lung cancer cell lines but only 5–15% of primary lung adenocarcinomas. There is evidence that homozygous deletion (HD) of chromosome 19p at the LKB locus contributes to the inactivation of the gene in primary human lung cancers. Here, we used several complementary genetic approaches to assess the LKB1 locus in primary non-small cell lung cancers (NSCLCs). We first analyzed 124 NSCLC cases for allelic imbalance using eight microsatellite markers on chromosome 19p, which revealed an overall rate of 65% (80 of 124) loss of heterozygosity (LOH). We next used chromogenic in situ hybridization (CISH) to directly examine the chromosomal status of the LKB1 locus. In all, 65 of 124 LOH tested samples were available for CISH and 58 of those (89%) showed either loss of one copy of chromosome 19p (LOH, 40 of 65 cases, 62%) or both copies (HD 18 of 65 cases, 28%). The occurrence of HD was significantly more frequent in Caucasian (35%) than in African-American patients (6%) (P=0.04). A total of 62 of 124 samples with LOH at one or both markers immediately flanking the LKB1 gene were further analyzed by directly sequencing the complete coding region, which identified 7 of 62 (11%) tumors with somatic mutations in the gene. Jointly, our data identified total inactivation of the LKB1 gene by either HD or LOH with somatic mutation in 39% of tested samples, whereas loss of chromosome 19p region by HD or LOH at the LKB1 region occured in 90% of NSCLC.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Alessi DR, Sakamoto K, Bayascas JR . (2006). LKB1-dependent signaling pathways. Annu Rev Biochem 75: 137–163.
Avizienyte E, Loukola A, Roth S, Hemminki A, Tarkkanen M, Salovaara R et al. (1999). LKB1 somatic mutations in sporadic tumors. Am J Pathol 154: 677–681.
Avizienyte E, Roth S, Loukola A, Hemminki A, Lothe RA, Stenwig AE et al. (1998). Somatic mutations in LKB1 are rare in sporadic colorectal and testicular tumors. Cancer Res 58: 2087–2090.
Bignell GR, Barfoot R, Seal S, Collins N, Warren W, Stratton MR . (1998). Low frequency of somatic mutations in the LKB1/Peutz-Jeghers syndrome gene in sporadic breast cancer. Cancer Res 58: 1384–1386.
Cairns P, Polascik TJ, Eby Y, Tokino K, Califano J, Merlo A et al. (1995). Frequency of homozygous deletion at p16/CDKN2 in primary human tumours. Nat Genet 11: 210–212.
Carretero J, Medina PP, Pio R, Montuenga LM, Sanchez-Cespedes M . (2004). Novel and natural knockout lung cancer cell lines for the LKB1/STK11 tumor suppressor gene. Oncogene 23: 4037–4040.
Conde E, Suarez-Gauthier A, Garcia-Garcia E, Lopez-Rios F, Lopez-Encuentra A, Garcia-Lujan R et al. (2007). Specific pattern of LKB1 and phospho-acetyl-CoA carboxylase protein immunostaining in human normal tissues and lung carcinomas. Hum Pathol 38: 1351–1360.
Corradetti MN, Inoki K, Bardeesy N, DePinho RA, Guan KL . (2004). Regulation of the TSC pathway by LKB1: evidence of a molecular link between tuberous sclerosis complex and Peutz-Jeghers syndrome. Genes Dev 18: 1533–1538.
Davies H, Hunter C, Smith R, Stephens P, Greenman C, Bignell G et al. (2005). Somatic mutations of the protein kinase gene family in human lung cancer. Cancer Res 65: 7591–7595.
Ding L, Getz G, Wheeler DA, Mardis ER, McLellan MD, Cibulskis K et al. (2008). Somatic mutations affect key pathways in lung adenocarcinoma. Nature 455: 1069–1075.
Gill RK, Vazquez MF, Kramer A, Hames M, Zhang L, Heselmeyer-Haddad K et al. (2008). The use of genetic markers to identify lung cancer in fine needle aspiration samples. Clin Cancer Res 14: 7481–7487.
Glaros S, Cirrincione GM, Palanca A, Metzger D, Reisman D . (2008). Targeted knockout of BRG1 potentiates lung cancer development. Cancer Res 68: 3689–3696.
Guldberg P, thor Straten P, Ahrenkiel V, Seremet T, Kirkin AF, Zeuthen J . (1999). Somatic mutation of the Peutz-Jeghers syndrome gene, LKB1/STK11, in malignant melanoma. Oncogene 18: 1777–1780.
Gurumurthy S, Hezel AF, Sahin E, Berger JH, Bosenberg MW, Bardeesy N . (2008). LKB1 deficiency sensitizes mice to carcinogen-induced tumorigenesis. Cancer Res 68: 55–63.
Hahn SA, Schutte M, Hoque AT, Moskaluk CA, da Costa LT, Rozenblum E et al. (1996). DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 271: 350–353.
Hawley SA, Boudeau J, Reid JL, Mustard KJ, Udd L, Makela TP et al. (2003). Complexes between the LKB1 tumor suppressor, STRAD alpha/beta and MO25 alpha/beta are upstream kinases in the AMP-activated protein kinase cascade. J Biol 2: 28.
Hemminki A, Markie D, Tomlinson I, Avizienyte E, Roth S, Loukola A et al. (1998). A serine/threonine kinase gene defective in Peutz-Jeghers syndrome. Nature 391: 184–187.
Inoki K, Zhu T, Guan KL . (2003). TSC2 mediates cellular energy response to control cell growth and survival. Cell 115: 577–590.
Jansen M, Ten Klooster JP, Offerhaus GJ, Clevers H . (2009). LKB1 and AMPK family signaling: the intimate link between cell polarity and energy metabolism. Physiol Rev 89: 777–798.
Ji H, Ramsey MR, Hayes DN, Fan C, McNamara K, Kozlowski P et al. (2007). LKB1 modulates lung cancer differentiation and metastasis. Nature 448: 807–810.
Koh HJ, Arnolds DE, Fujii N, Tran TT, Rogers MJ, Jessen N et al. (2006). Skeletal muscle-selective knockout of LKB1 increases insulin sensitivity, improves glucose homeostasis, and decreases TRB3. Mol Cell Biol 26: 8217–8227.
Koivunen JP, Kim J, Lee J, Rogers AM, Park JO, Zhao X et al. (2008). Mutations in the LKB1 tumour suppressor are frequently detected in tumours from Caucasian but not Asian lung cancer patients. Br J Cancer 99: 245–252.
Launonen V . (2005). Mutations in the human LKB1/STK11 gene. Hum Mutat 26: 291–297.
Levin NA, Brzoska PM, Warnock ML, Gray JW, Christman MF . (1995). Identification of novel regions of altered DNA copy number in small cell lung tumors. Genes Chromosomes Cancer 13: 175–185.
Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI et al. (1997). PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275: 1943–1947.
Lim W, Hearle N, Shah B, Murday V, Hodgson SV, Lucassen A et al. (2003). Further observations on LKB1/STK11 status and cancer risk in Peutz-Jeghers syndrome. Br J Cancer 89: 308–313.
Lukeis R, Irving L, Garson M, Hasthorpe S . (1990). Cytogenetics of non-small cell lung cancer: analysis of consistent non-random abnormalities. Genes Chromosomes Cancer 2: 116–124.
Luukko K, Ylikorkala A, Tiainen M, Makela TP . (1999). Expression of LKB1 and PTEN tumor suppressor genes during mouse embryonic development. Mech Dev 83: 187–190.
Matsumoto S, Iwakawa R, Takahashi K, Kohno T, Nakanishi Y, Matsuno Y et al. (2007). Prevalence and specificity of LKB1 genetic alterations in lung cancers. Oncogene 26: 5911–5918.
Mechanic LE, Marrogi AJ, Welsh JA, Bowman ED, Khan MA, Enewold L et al. (2005). Polymorphisms in XPD and TP53 and mutation in human lung cancer. Carcinogenesis 26: 597–604.
Medina PP, Romero OA, Kohno T, Montuenga LM, Pio R, Yokota J et al. (2008). Frequent BRG1/SMARCA4-inactivating mutations in human lung cancer cell lines. Hum Mutat 29: 617–622.
Rowan A, Bataille V, MacKie R, Healy E, Bicknell D, Bodmer W et al. (1999). Somatic mutations in the Peutz-Jeghers (LKB1/STKII) gene in sporadic malignant melanomas. J Invest Dermatol 112: 509–511.
Sanchez-Cespedes M, Ahrendt SA, Piantadosi S, Rosell R, Monzo M, Wu L et al. (2001). Chromosomal alterations in lung adenocarcinoma from smokers and nonsmokers. Cancer Res 61: 1309–1313.
Sanchez-Cespedes M, Parrella P, Esteller M, Nomoto S, Trink B, Engles JM et al. (2002). Inactivation of LKB1/STK11 is a common event in adenocarcinomas of the lung. Cancer Res 62: 3659–3662.
Shaw RJ, Bardeesy N, Manning BD, Lopez L, Kosmatka M, DePinho RA et al. (2004a). The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell 6: 91–99.
Shaw RJ, Kosmatka M, Bardeesy N, Hurley RL, Witters LA, DePinho RA et al. (2004b). The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. Proc Natl Acad Sci USA 101: 3329–3335.
Shaw RJ, Lamia KA, Vasquez D, Koo SH, Bardeesy N, Depinho RA et al. (2005). The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 310: 1642–1646.
Steck PA, Pershouse MA, Jasser SA, Yung WK, Lin H, Ligon AH et al. (1997). Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 15: 356–362.
Virmani AK, Fong KM, Kodagoda D, McIntire D, Hung J, Tonk V et al. (1998). Allelotyping demonstrates common and distinct patterns of chromosomal loss in human lung cancer types. Genes Chromosomes Cancer 21: 308–319.
Wang ZJ, Taylor F, Churchman M, Norbury G, Tomlinson I . (1998). Genetic pathways of colorectal carcinogenesis rarely involve the PTEN and LKB1 genes outside the inherited hamartoma syndromes. Am J Pathol 153: 363–366.
Wingo SN, Gallardo TD, Akbay EA, Liang MC, Contreras CM, Boren T et al. (2009). Somatic LKB1 mutations promote cervical cancer progression. PLoS One 4: e5137.
Woods A, Johnstone SR, Dickerson K, Leiper FC, Fryer LG, Neumann D et al. (2003). LKB1 is the upstream kinase in the AMP-activated protein kinase cascade. Curr Biol 13: 2004–2008.
Zhang S, Schafer-Hales K, Khuri FR, Zhou W, Vertino PM, Marcus AI . (2008). The tumor suppressor LKB1 regulates lung cancer cell polarity by mediating cdc42 recruitment and activity. Cancer Res 68: 740–748.
Zhong D, Guo L, de Aguirre I, Liu X, Lamb N, Sun SY et al. (2006). LKB1 mutation in large cell carcinoma of the lung. Lung Cancer 53: 285–294.
Acknowledgements
We thank John Cottrell, Ray Jones, Audrey Salabes and Mike Lipsky at University of Maryland Medical Center for tissue collection and clinical information. We thank the members of Dr. Thomas Reid's lab for technical support during the course of this study. We thank Ms Stacy Johnson for editorial and graphical/technical assistance. The current addresses are RKG, Laboratory of Receptor Biology and Gene Expression, National Cancer Institute, Bethesda, MD 20892–4258; SHY, Wonkwang University Hospital, Department of Pulmonary and Critical Care Medicine, Iksan, South Korea; HSJ, Laboratory of Biochemistry and Cell Biology, Kyungpook National University, School of Medicine, Deagu, South Korea; SRC, Laboratory of Pathology, National Cancer Institute, Bethesda, MD; AS, Department of Medical Genetics, Tehran University of Medical Sciences, Cancer Institute Hospital, Tehran, Iran; TVD, J. Craig Venter Institute, Rockville, MD; KMH, National Cancer Center, Cancer Cell and Molecular Biology Branch, Goyang, Korea; JF, Toyama University Hospital, Department of Surgical Pathology, Toyama, Japan; and JHZ, St. Jude Children's Research Hospital, Biotechnology, Memphis, TN. This work was supported by intramural research funds from the Center for Cancer Research at CCR and funds for JJ from the Mayo Cancer Center and Center for Individualized Medicine, Rochester, MN.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Gill, R., Yang, SH., Meerzaman, D. et al. Frequent homozygous deletion of the LKB1/STK11 gene in non-small cell lung cancer. Oncogene 30, 3784–3791 (2011). https://doi.org/10.1038/onc.2011.98
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/onc.2011.98
Keywords
This article is cited by
-
Caloric restriction and metformin selectively improved LKB1-mutated NSCLC tumor response to chemo- and chemo-immunotherapy
Journal of Experimental & Clinical Cancer Research (2024)
-
Lung adenocarcinomas without driver genes converge to common adaptive strategies through diverse genetic, epigenetic, and niche construction evolutionary pathways
Medical Oncology (2024)
-
A phase II study of metformin plus pemetrexed and carboplatin in patients with non-squamous non-small cell lung cancer (METALUNG)
Medical Oncology (2023)
-
Loss of LKB1-NUAK1 signalling enhances NF-κB activity in a spheroid model of high-grade serous ovarian cancer
Scientific Reports (2022)
-
LKB1 phosphorylation and deactivation in lung cancer by NNAL, a metabolite of tobacco-specific carcinogen, in an isomer-dependent manner
Oncogene (2022)